MCID: ALL026
MIFTS: 62

Allergic Hypersensitivity Disease

Categories: Immune diseases

Aliases & Classifications for Allergic Hypersensitivity Disease

MalaCards integrated aliases for Allergic Hypersensitivity Disease:

Name: Allergic Hypersensitivity Disease 12 15
Hypersensitivity 12 74 43 71
Allergic Disposition 71
Allergic Condition 71
Allergic Diseases 15
Allergic Reaction 71
Allergic Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1205
MeSH 43 D006967
NCIt 49 C3114
SNOMED-CT 67 418634005
ICD10 32 T78.40
UMLS 71 C0020517 C0851444 C1527304 more

Summaries for Allergic Hypersensitivity Disease

Disease Ontology : 12 An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods.

MalaCards based summary : Allergic Hypersensitivity Disease, also known as hypersensitivity, is related to hypersensitivity reaction type iii disease and hypersensitivity reaction type iv disease, and has symptoms including pruritus, nausea and vomiting and abdominal pain. An important gene associated with Allergic Hypersensitivity Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fentanyl and Rocuronium have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and t cells, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 74 Hypersensitivity (also called hypersensitivity reaction or intolerance) refers to undesirable reactions... more...

Related Diseases for Allergic Hypersensitivity Disease

Diseases related to Allergic Hypersensitivity Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1915)
# Related Disease Score Top Affiliating Genes
1 hypersensitivity reaction type iii disease 34.7 TNF ICOSLG CCR6
2 hypersensitivity reaction type iv disease 34.5 TNF IL4 IL2 IL10 IFNG ICOSLG
3 nut allergy 34.2 IL5 IL13 CCR6
4 bronchiolitis obliterans 33.0 TNF IL13 IL10 IFNG CXCL8
5 erythema multiforme 33.0 TNF IL5 IL4 IL2 IL13 IFNG
6 igg4-related disease 33.0 IL4 ICOSLG CCR6
7 pulmonary sarcoidosis 32.9 TNF IL2 IFNG CSF2 CCR6 CCL5
8 sarcoidosis 1 32.9 TNF IL2 IL13 IFNG ICOSLG CCR6
9 juvenile myelomonocytic leukemia 32.9 IL4 IL13 IL10 CSF2
10 alopecia areata 32.9 TNF IL4 IL2 IL13 IL10 IFNG
11 familial mediterranean fever 32.8 TNF IL10 CXCL8
12 allergic asthma 32.8 RNASE3 IL5 IL4 IL3 IL13 IL10
13 esophagitis, eosinophilic, 1 32.8 RNASE3 IL5 IL4 IL3 IL13 ICOSLG
14 bullous pemphigoid 32.7 TNF RNASE3 IL5 IL4 IL13 FCER2
15 toxicodendron dermatitis 32.6 TNF IL2 CXCL8
16 cardiac sarcoidosis 32.5 TNF IL5 IFNG CXCL8
17 mikulicz disease 32.5 IL5 IL4 IL13 IL10 CCR6
18 dermatitis, atopic 32.5 TNF RNASE3 IL5 IL4 IL2 IL13
19 cryoglobulinemia 32.5 TNF IL10 IFNG
20 autoimmune disease of cardiovascular system 32.5 TNF ICOSLG CCR6
21 autoimmune disease of exocrine system 32.5 TNF IL4 IL10 ICOSLG CCR6
22 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 32.5 IL4 IL2 IL10 ICOSLG CCR6
23 autoimmune disease of eyes, ear, nose and throat 32.4 TNF IL4 IL2 IL10 ICOSLG CCR6
24 autoimmune lymphoproliferative syndrome 32.4 TNF IL2 IL10 ICOSLG
25 autoimmune disease of blood 32.4 TNF IL5 IL4 IL2 IL10 ICOSLG
26 autoimmune disease of skin and connective tissue 32.4 TNF IL4 IL2 IL10 IFNG ICOSLG
27 autoimmune disease of endocrine system 32.4 TNF IL4 IL2 IL10 IFNG ICOSLG
28 autoimmune disease of gastrointestinal tract 32.4 TNF IL4 IL2 IL10 IFNG ICOSLG
29 ige responsiveness, atopic 32.3 RNASE3 IL5 IL4 IL13 IL10 IFNG
30 autoimmune disease of musculoskeletal system 32.3 TNF IL4 IL2 IL10 IFNG ICOSLG
31 rhinitis 32.2 TNF RNASE3 IL5 IL4 IL13 IL10
32 pollen allergy 32.1 RNASE3 IL5 IL3 IL13
33 food allergy 32.1 TNF RNASE3 IL5 IL4 IL13 IL10
34 dermatitis 32.1 TNF IL5 IL4 IL2 IL13 IL10
35 autoimmune disease of central nervous system 32.0 TNF IL5 IL4 IL2 IL13 IL10
36 allergic rhinitis 32.0 RNASE3 IL5 IL4 IL13 IL10 IFNG
37 urticaria 32.0 TNF RNASE3 IL5 IL4 IL13 IL10
38 conjunctivitis 31.7 TNF RNASE3 IL5 IL4 IL2 IL13
39 stevens-johnson syndrome/toxic epidermal necrolysis 31.7 IL5 IL2 IL13 IFNG CCR3 CCL5
40 allergic conjunctivitis 31.7 TNF RNASE3 IL5 IL4 IL2 IL13
41 interstitial lung disease 31.5 TNF IL5 IL4 IL13 IL10 IFNG
42 milk allergy 31.5 TNF RNASE3 IL5 IL4 IL13 IL10
43 cytokine deficiency 31.5 IL5 IL13
44 alopecia 31.5 TNF IL4 IL2 IFNG
45 contact dermatitis 31.4 TNF IL5 IL4 IL2 IL10 IFNG
46 leishmaniasis 31.3 TNF IL5 IL4 IL2 IL13 IL10
47 peripheral nervous system disease 31.3 TNF IL4 IL2 IL10 IFNG ICOSLG
48 irritant dermatitis 31.3 TNF IL4 CXCL8
49 bronchitis 31.3 TNF RNASE3 IL5 IL4 IL13 IL10
50 granulocytopenia 31.3 TNF IL3 CSF2

Graphical network of the top 20 diseases related to Allergic Hypersensitivity Disease:



Diseases related to Allergic Hypersensitivity Disease

Symptoms & Phenotypes for Allergic Hypersensitivity Disease

UMLS symptoms related to Allergic Hypersensitivity Disease:


pruritus, nausea and vomiting, abdominal pain, syncope, stridor, tinnitus, snoring, sore throat, exanthema, coughing, vertigo/dizziness, equilibration disorder, signs and symptoms of ill-defined conditions, (non-specific) malaise and fatigue, injection site hypersensitivity, fever of unknown origin

MGI Mouse Phenotypes related to Allergic Hypersensitivity Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 CCL11 CCL17 CCL24 CCL5 CCR3 CCR6
2 digestive/alimentary MP:0005381 9.86 FCER2 IFNG IL10 IL13 IL2 IL4
3 immune system MP:0005387 9.86 CCL11 CCL17 CCL24 CCL5 CCR3 CCR6
4 respiratory system MP:0005388 9.36 CCL11 CCL24 CCR3 CSF2 IFNG IL10

Drugs & Therapeutics for Allergic Hypersensitivity Disease

Drugs for Allergic Hypersensitivity Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
2
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
6
Dapsone Approved, Investigational Phase 4 80-08-0 2955
7
Nifedipine Approved Phase 4 21829-25-4 4485
8
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
9
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
12
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
13
Losartan Approved Phase 4 114798-26-4 3961
14
Amlodipine Approved Phase 4 88150-42-9 2162
15
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
16
Linagliptin Approved Phase 4 668270-12-0 10096344
17
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
18
Rilpivirine Approved Phase 4 500287-72-9
19
Cobicistat Approved Phase 4 1004316-88-4
20
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
21
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
22
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
23
Montelukast Approved Phase 4 158966-92-8 5281040
24
Epinastine Approved, Investigational Phase 4 80012-43-7 3241
25
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
26
Glycerol Approved, Investigational Phase 4 56-81-5 753
27
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
28
Calcium carbonate Approved, Investigational Phase 4 471-34-1
29
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
30
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
31
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
32
Ibuprofen Approved Phase 4 15687-27-1 3672
33
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
34
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
35
Thrombin Approved, Investigational Phase 4
36
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
37
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
38
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
39
Mycophenolic acid Approved Phase 4 24280-93-1 446541
40
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
41
Clevidipine Approved, Investigational Phase 4 167221-71-8
42
Dipyridamole Approved Phase 4 58-32-2 3108
43
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
44
Cetirizine Approved Phase 4 83881-51-0 2678
45
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
46
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
47
Levetiracetam Approved Phase 4 102767-28-2 441341
48
Benzoyl peroxide Approved Phase 4 94-36-0 7187
49
Levocetirizine Approved Phase 4 130018-77-8 1549000
50
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594

Interventional clinical trials:

(show top 50) (show all 3082)
# Name Status NCT ID Phase Drugs
1 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
2 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
3 Botulinum Toxin to Improve Lower Blepharoplasty Scar Unknown status NCT02786550 Phase 4 Botulinum Toxin
4 The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers: A Randomized Controlled Trial. Unknown status NCT03021161 Phase 4 Probiotic Formula
5 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
6 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
7 Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
8 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
9 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
10 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
11 Healing Nipple Wounds: Comparison Between 2 Treatment Modalities: Lanolin Ointmentnad Nursicare Therapeutic Breast Pads Among Postpartum Mothers Dealing With Sore Nipples Unknown status NCT03389516 Phase 4
12 The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study Unknown status NCT02550093 Phase 4 Normal Saline;Oxytocin
13 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
14 Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams Unknown status NCT01159379 Phase 4 ertapenem
15 Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals Unknown status NCT01253928 Phase 4 Pioglitazone
16 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
17 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
18 A MULTICENTRE RANDOMIZED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF TEGADERM CHG IN REDUCING CATHETER RELATED BLOOD STREAM INFECTIONS Unknown status NCT01142934 Phase 4
19 Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial Unknown status NCT01761149 Phase 4 Remifentanil
20 N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
21 Single Centre,Randomized,Phase IV Study to Assess the Topical r-Hirudin (Thrombexx)Efficacy in the Patients With Haematomas Unknown status NCT01960569 Phase 4 active product ( Thrombexx) assigned to arm 1
22 A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients Unknown status NCT01431859 Phase 4
23 Fludrocortisone's Test in the Identification of Salt Sensitivity Unknown status NCT01453959 Phase 4 Fludrocortisone
24 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
25 A Comparison of Post-Incisional Wound Infiltration of Liposomal Bupivacaine to Plain Bupivacaine for Post-Operative Pain Control in Elective Cesarean Delivery: A Randomized Double Blind Placebo Controlled Trial Unknown status NCT03353363 Phase 4 Bupivacaine;Liposomal bupivacaine;Placebos
26 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
27 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
28 The Effect of Bupivacaine (Marcaine) in Reducing Early Post Tonsillectomy Pain Unknown status NCT01582022 Phase 4 Bupivacaine;normal saline
29 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
30 Distribution and Expression of Non-neuronal Transient Receptor Potential (TRPV) Ion Channels in Sensitive Skin Syndrome. Unknown status NCT01871883 Phase 4
31 Management of Recurrent Pterygium to Prevent Visual Impairment Unknown status NCT02530801 Phase 4 Bevacizumab;5 fluorouracil
32 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
33 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
34 Non-surgical Treatment of Carpal Tunnel Syndrome: Night Splint Versus Local Corticosteroid Infiltration: Clinical Randomized Trial Unknown status NCT03196817 Phase 4 betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%
35 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
36 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
37 Effect of Controlled Hypotension on Cerebral Oxygen Saturation in Patients Undergoing Functional Endoscopic Sinus Surgery: a Prospective Randomized Single Blind Clinical Trial Unknown status NCT02967029 Phase 4 Esmolol Hydrochloride;Remifentanil Hydrochloride
38 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
39 Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome Unknown status NCT02049229 Phase 4
40 Recovery of Muscle Function After Deep Neuromuscular Block by Means of Dia-phragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs. Sugammadex as Reversal Drugs. Unknown status NCT02698969 Phase 4 Sugammadex;Neostigmine;Atropine;Rocuronium;Fentanyl;Propofol;Sevoflurane
41 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
42 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
43 Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction? Completed NCT00716963 Phase 4 Fluticasone propionate (Flovent Diskus) 250 mcg;budesonide 400 mcg
44 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Completed NCT01966640 Phase 4
45 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
46 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. A Prospective, Randomised, Clinical Trial. Completed NCT01694108 Phase 4
47 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
48 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
49 Hyaluronic Acid-Carboxymethylcellulose Reduced Postoperative Bowel Adhesions Following Laparoscopic Urologic Pelvic Surgery: a Prospective, Randomized, Controlled, Single-Blind Study Completed NCT02773251 Phase 4 hyaluronic acid-carboxymethylcellulose
50 Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) Completed NCT00367016 Phase 4 Xolair (Omalizumab);Placebo

Search NIH Clinical Center for Allergic Hypersensitivity Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR

Cochrane evidence based reviews: hypersensitivity

Genetic Tests for Allergic Hypersensitivity Disease

Anatomical Context for Allergic Hypersensitivity Disease

MalaCards organs/tissues related to Allergic Hypersensitivity Disease:

40
Testes, Skin, T Cells, Lung, Breast, Prostate, Liver

Publications for Allergic Hypersensitivity Disease

Articles related to Allergic Hypersensitivity Disease:

(show top 50) (show all 30332)
# Title Authors PMID Year
1
IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. 54 61
20357258 2010
2
IgE, mast cells, basophils, and eosinophils. 61 54
20176269 2010
3
Genetic determinants of both ethanol and acetaldehyde metabolism influence alcohol hypersensitivity and drinking behaviour among Scandinavians. 54 61
20205700 2010
4
Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? 54 61
19563991 2009
5
Hypersensitivity to proton pump inhibitors: lansoprazole-induced Kounis syndrome. 54 61
18378022 2009
6
Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. 61 54
19473578 2009
7
CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. 61 54
18005225 2008
8
Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. 61 54
17873578 2007
9
[Type IV of hypersensitivity and its subtypes]. 61 54
18409354 2007
10
Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. 61 54
17008937 2006
11
Abacavir hypersensitivity reaction in primary HIV infection. 61 54
16816555 2006
12
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. 54 61
16393267 2006
13
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. 61 54
15867870 2005
14
The application of a monoclonal antibody to CD62L on paraffin-embedded tissue samples in the assessment of the cutaneous T-cell infiltrates. 61 54
15660650 2005
15
Anti-IgE therapy. 61 54
15474858 2004
16
Quantitative assessment of immediate cutaneous hypersensitivity in a mouse model exhibiting an IgE response to Timothy grass allergens. 54 61
14646968 2003
17
Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? 61 54
14677170 2003
18
Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. 61 54
12974198 2003
19
Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. 61 54
12706535 2003
20
Specific delayed-type hypersensitivity responses to ESAT-6 identify tuberculosis-infected cattle. 61 54
12734217 2003
21
L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. 61 54
12682269 2003
22
Influence of human T-cell lymphocytotropic virus type 1 infection on serologic and skin tests for strongyloidiasis. 54 61
11716123 2001
23
Phenotypic characterization of human CD4+ regulatory T cells obtained from cutaneous dinitrochlorobenzene-induced delayed type hypersensitivity reactions. 61 54
11511310 2001
24
TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. 61 54
11294926 2001
25
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 61 54
11261930 2001
26
Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. 54 61
11085746 2000
27
Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. 54 61
10994772 2000
28
Il-4 and IFN-gamma mRNA induction in human peripheral lymphocytes specific for beta-lactam antibiotics in immediate or delayed hypersensitivity reactions. 61 54
10821462 2000
29
Use of alkaline rinsing solution to prevent hypersensitivity reactions during hemodialysis: data from a multicentre retrospective analysis. 61 54
10626828 1999
30
Induction and regulation of the IgE response. 61 54
10586891 1999
31
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. 54 61
10480916 1999
32
Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. 54 61
10458510 1999
33
Increased soluble ICAM-1 concentration and impaired delayed-type hypersensitivity skin tests in patients with chronic liver disease. 61 54
9059357 1997
34
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. 54 61
8551232 1996
35
Expression and inducibility of antigens in severe combined immunodeficient mice recognized by human anti-P450 antibodies. 54 61
7482543 1995
36
Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. 54 61
7666481 1995
37
Cytokines and their role in the pathogenesis of severe food hypersensitivity reactions. 54 61
8214800 1993
38
Pentoxifylline suppresses irritant and contact hypersensitivity reactions. 54 61
8409522 1993
39
Immunological aspects and inflammatory mechanisms of allergic reactions. 61 54
8517144 1993
40
Cutaneous hypersensitivity to co-trimoxazole after autologus bone marrow transplantation and immunotherapy with interferon alpha-2A and interleukin-2. 54 61
8270579 1993
41
Induction of mast cell sensitization by chemical allergens: a comparative study. 54 61
8486912 1993
42
Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s) 54 61
8447835 1993
43
Production and isolation of guinea pig IgE antibody. 54 61
2040810 1991
44
Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2. 61 54
2037319 1991
45
Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. 61 54
2311064 1990
46
Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. 61
32464241 2020
47
Effects of hypersensitivity disorders and environmental factors on the equine intestinal microbiota. 61
32189583 2020
48
Altered levels of complement components associated with non-immediate drug hypersensitivity reactions. 61
31795786 2020
49
Congenital ichthyosis associated with Trichophyton rubrum tinea, imitating drug hypersensitivity reaction. 61
32547912 2020
50
Continuous infusion of substance P into rat striatum relieves mechanical hypersensitivity caused by a partial sciatic nerve ligation via activation of striatal muscarinic receptors. 61
32461131 2020

Variations for Allergic Hypersensitivity Disease

Expression for Allergic Hypersensitivity Disease

Search GEO for disease gene expression data for Allergic Hypersensitivity Disease.

Pathways for Allergic Hypersensitivity Disease

Pathways related to Allergic Hypersensitivity Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 TNF RNASE3 IL5 IL4 IL3 IL2
2
Show member pathways
13.93 TNF IL5 IL4 IL3 IL2 IL13
3
Show member pathways
13.66 TNF IL5 IL4 IL3 IL2 IL13
4
Show member pathways
13.5 TNF IL5 IL4 IL3 IL2 IL13
5
Show member pathways
13.13 TNF IL5 IL4 IL3 IL2 IL13
6
Show member pathways
13.09 TNF IL2 IL10 IFNG CXCL8 CCL5
7
Show member pathways
13.02 HRH4 CXCL8 CCR6 CCR3 CCL5 CCL24
8
Show member pathways
13.01 TNF RNASE3 IL5 IL4 IL3 IL2
9
Show member pathways
13.01 TNF IL5 IL4 IL3 IL2 IL13
10 12.95 IL5 IL4 IL3 IL2 IL13 IFNG
11
Show member pathways
12.92 TNF IL5 IL4 IL3 IL2 IL13
12
Show member pathways
12.89 TNF IL2 IFNG FCER2 CXCL8 CCL5
13
Show member pathways
12.74 TNF IL5 IL4 IL2 IL10 IFNG
14
Show member pathways
12.73 TNF IL4 IL2 IL10 IFNG ICOSLG
15
Show member pathways
12.73 TNF IL5 IL4 IL2 IL13 IL10
16 12.71 TNF IL4 IL3 IL2 IL10 IFNG
17
Show member pathways
12.7 TNF IL5 IL4 IL3 IL13 CSF2
18
Show member pathways
12.63 TNF IL4 IL3 IL2 IFNG CSF2
19
Show member pathways
12.62 IL5 IL4 IL3 IL2 IL13 IL10
20
Show member pathways
12.52 TNF IL5 IL4 IL13 IFNG CXCL8
21
Show member pathways
12.51 TNF IL2 IL10 CXCL8 CCR6 CCR3
22
Show member pathways
12.45 TNF IL5 IL4 IL3 IL2 IL13
23
Show member pathways
12.44 CXCL8 CCR3 CCL5 CCL24 CCL11
24
Show member pathways
12.43 TNF IL4 IL2 IFNG CCL5
25 12.42 TNF CXCL8 CSF2 CCL5
26
Show member pathways
12.3 TNF IL4 IL10 IFNG
27
Show member pathways
12.3 TNF IL4 IFNG CXCL8 CCL11
28
Show member pathways
12.26 TNF IL2 IL10 CCL17
29 12.23 TNF IL13 IL10 CXCL8
30
Show member pathways
12.2 IL5 IL3 IL2 CSF2
31 12.19 TNF IL4 IL13 IL10 FCER2 CXCL8
32 12.17 TNF IL5 IL4 IL3 IL2 IL10
33 12.15 TNF IL4 IL2 IFNG CXCL8
34 12.1 TNF IL5 IL4 IL3 FCER2 CSF2
35 12.09 TNF IL2 IL10 CXCL8
36 12.08 TNF IL10 IFNG CXCL8 CSF2
37
Show member pathways
12.03 TNF IL2 IL10 IFNG
38 12.03 TNF IFNG CXCL8 CSF2 CCL5
39 12.03 IL5 IL4 IL2 IL13 IFNG CXCL8
40 12.03 TNF IL5 IL4 IL2 IL13 IL10
41
Show member pathways
11.99 TNF IL5 IL4 IL3 IL2 IFNG
42 11.91 TNF IL2 IL10 IFNG CSF2
43 11.87 IL5 IL4 IL10 FCER2 CCL17 CCL11
44
Show member pathways
11.83 TNF IL2 IFNG CXCL8 CSF2
45 11.82 TNF IL5 IL4 IL13 CXCL8 CSF2
46 11.79 TNF IL10 CXCL8
47 11.7 IL5 IL4 IL2 IL13 IL10 IFNG
48 11.7 TNF IL4 IL13 IL10 FCER2 CXCL8
49
Show member pathways
11.69 TNF IL2 IFNG
50 11.68 TNF IL10 IFNG CXCL8

GO Terms for Allergic Hypersensitivity Disease

Cellular components related to Allergic Hypersensitivity Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNF RNASE3 IL5 IL4 IL3 IL2
2 cell GO:0005623 9.8 IL2 IL13 HRH4 CCR6 CCR3 CCL5
3 external side of plasma membrane GO:0009897 9.63 TNF IL13 ICOSLG FCER2 CCR6 CCR3
4 extracellular space GO:0005615 9.5 TNF RNASE3 IL5 IL4 IL3 IL2

Biological processes related to Allergic Hypersensitivity Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 68) <
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 IL5 IL4 IL10 ICOSLG HRH4 CXCL8
2 G protein-coupled receptor signaling pathway GO:0007186 10.23 IL2 HRH4 CXCL8 CCR6 CCR3 CCL5
3 positive regulation of cell proliferation GO:0008284 10.14 IL5 IL4 IL3 IL2 IFNG CSF2
4 positive regulation of gene expression GO:0010628 10.13 TNF IL4 IL13 IFNG CSF2
5 positive regulation of cell migration GO:0030335 10.04 IL4 CCL5 CCL24 CCL11
6 cell-cell signaling GO:0007267 10.03 IL3 IL2 CCL5 CCL24 CCL17
7 inflammatory response GO:0006954 10.02 TNF IL5 IL13 HRH4 CXCL8 CCR3